MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 58970-76-6
MCE 国际站:Bestatin
产品活性:Bestatin (Ubenimex) 是 CD13 (Aminopeptidase N)/APN 和 leukotriene A4 hydrolase 抑制剂,常用于癌症研究。
研究领域:Metabolic Enzyme/Protease | Anti-infection
作用靶点:Aminopeptidase | Bacterial | Antibiotic
结构分类:酮、醛、酸 | 结构分类
In Vitro: Bestatin enhances ATRA-induced differentiation and inhibits ATRA-driven phosphorylation of p38 MAPK in ATRA-sensitive APL NB4 cells. Bestatin can not reverse the differentiation block in ATRA-resistant APL MR2 cells. CD13 ligation with anti-CD13 antibody WM-15 results in phosphorylation of p38 MAPK, reduces the inhibition of Bestatin on the phosphorylation of p38 MAPK, and completely abolishes the enhancement of Bestatin on ATRA-inducing differentiation in NB4 cells. Bestatin (600 μM)-treated cells progress slower through the cell cycle due to decreased rate of cell growth and the frequency of cell division. Bestatin inhibits the frequency of mitosis and the inherent multinuclearity in D. discoideum, and is not cytotoxic to D. discoideum cells at 0-600 μM. Bestatin inhibits aminopeptidase activity in lysates of PsaA-GFP- and GFP-expressing cells by 69.39% and 39.93% of control, respectively.
In Vivo: Bestatin (20 μM) significantly reduces CD13 expression in diabetic mice and results a significant inhibition of MMP-9 specific gelationolytic band densities compared to diabetic vehicle-treated mice. Bestatin treatment significantly inhibits the expression of VEGF and heparanase in diabetic mice. Intravitreal bestatin treatment significantly downregulates the expression of both HIF-1α and VEGF in diabetic mice retinas. Furthermore, the upregulated expression of heparanase in diabetic mice retinas is significantly inhibited by intravitreal bestatin treatment. Bestatin (10, 1, and 0.1mg/kg, i.p.) treatment before the antigen-potentiated humoral response to SRBC results in an increased number of splenocytes producing hemolytic anti-SRBC antibodies (PFC) and the 2-ME-resistant serum hemagglutinin titer (at a dose of 0.1 mg/kg). Bestatin (1 and 0.1 mg/kg) administered to mice five times on alternate days after cyclophosphamide injection does not change the suppressive effect of the drug regarding the number of PFC, and even causes the further decrease of the total anti-SRBC hemagglutinins at dose of 1 mg/kg on day 7 after antigen stimulation.
相关产品:Natural Product Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Metabolism/Protease Compound Library | Natural Product Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Peptidomimetic Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Antibacterial Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | Microbial Metabolite Library | Rare Diseases Drug Library | Anti-Cancer Natural Product Library | FDA-Approved Anticancer Drug Library | Cancer Stem Cells Compound Library | Off-patent Drug Library | Myricetin 3-O-α-L-arabinopyranoside | (1R,2S,7R)-Sitafloxacin-d4 hydrochloride | Nebacumab | Doxorubicin-13C,d3 TFA | Gepotidacin | Amycolatopsin A | Antibiotic A-33853 | Estradiol hemihydrate | Sulbactam-d2 sodium | Antimicrobial agent-5 | NBTIs-IN-4 | Proanthocyanidins | Anticancer agent 120 | Azlocillin sodium salt | Antitubercular agent-13 | Toyocamycin | Lenampicillin hydrochloride | Hispolon | PC58538 | SPR206 acetate | Caracemide | Antimicrobial agent-10 | Doxycycline calcium | Antibacterial agent 138 | Staurosporine | Dihydrostreptomycin sulfate | Ciclopirox olamine | Rubropunctamine | Topoisomerase IV inhibitor 2 | Psoracorylifol C
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。